PARP inhibitor market to exceed USD 67 billion by 2034 at 18.30% CAGR, redefining cancer treatment landscape – From PMI
PMI “PARP Inhibitor Market” from 2024 to 2034, including target segments (PARP Inhibitor Market, by drug (Lynparza, Niraparib, Rucaparib, etc.), by indication (Ovarian Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, etc.) , by distribution channel (hospital pharmacies, online pharmacies, etc.), and regional forecasts, 2024-2034), provides the perfect combination of market strategy and industry expertise with … Read more